Added to YB: 2024-12-03
Pitch date: 2024-11-30
JANX [bearish]
Janux Therapeutics, Inc.
+61.08%
current return
Author Info
No bio for this author
Company Info
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer.
Market Cap
$1.0B
Pitch Price
$45.02
Price Target
25.00 (+43%)
Dividend
N/A
EV/EBITDA
-0.39
P/E
-9.99
EV/Sales
2.22
Sector
Biotechnology
Category
N/A
Janux Therapeutics: Short Thesis on Overhyped Early Success
JANX short: PSA50 below 65% expectation. Durability concerns at 7-8 months. Ph1 onc up 300%+ YTD, 1.9B EV primed for downside. PSMA failure risks EGFR. CEO sold 23% stake in 90 days. Delayed readout, CRS concerns. Ikarian has puts, BVF exited. Expect 50% haircut or slow bleed post-readout.
Read full article (2 min)